Viritis
Viritis Ltd, founded in 2022, is developing a next-generation, AI-driven antisense-based platform for the rapid development of antiviral drugs. Their patented molecule, EXHAUVIR, targets conserved regions of viral genetic material, triggering cellular mechanisms to degrade viruses without harming the host. Key advantages include effectiveness across all strains, resilience to mutations, room-temperature stability, and rapid adaptation to new threats. The platform integrates synthetic biology, AI, and molecular targeting, aiming to create a scalable solution for both current and emerging viral diseases, with potential expansion into oncology and rare genetic disorders. Viritis has received recognition through the NVIDIA Inception Program and a grant from the Israeli Innovation Authority.
Viritis
Viritis Ltd, founded in 2022, is developing a next-generation, AI-driven antisense-based platform for the rapid development of antiviral drugs. Their patented molecule, EXHAUVIR, targets conserved regions of viral genetic material, triggering cellular mechanisms to degrade viruses without harming the host. Key advantages include effectiveness across all strains, resilience to mutations, room-temperature stability, and rapid adaptation to new threats. The platform integrates synthetic biology, AI, and molecular targeting, aiming to create a scalable solution for both current and emerging viral diseases, with potential expansion into oncology and rare genetic disorders. Viritis has received recognition through the NVIDIA Inception Program and a grant from the Israeli Innovation Authority.